Publications by authors named "Stuart J Bevan"

Claim this Profile
S
Sulfonamido-aryl ethers as bradykinin B1 receptor antagonists.
Andrew G Cole, Axel Metzger, Marc-Raleigh Brescia, Lan-Ying Qin, Kenneth C Appell, Stuart J Bevan

Bioorg Med Chem Lett· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2.
Osamu Irie, Takatoshi Kosaka, Masashi Kishida, Junichi Sakaki, Keiichi Masuya, Stuart J Bevan

Bioorg Med Chem Lett· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain.
Osamu Irie, Takatoshi Kosaka, Takeru Ehara, Fumiaki Yokokawa, Takanori Kanazawa, Stuart J Bevan

J Med Chem· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
Edward K Dziadulewicz, Stuart J Bevan, Christopher T Brain, Paul R Coote, Andrew J Culshaw

J Med Chem· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core.
Timothy J Ritchie, Edward K Dziadulewicz, Andrew J Culshaw, Werner Müller, Gillian M Burgess, Stuart J Bevan

J Med Chem· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis